bioSeedin’s Post

View organization page for bioSeedin, graphic

5,550 followers

𝐌𝐞𝐧𝐭𝐞𝐧 𝐀𝐈 𝐀𝐧𝐧𝐨𝐮𝐧𝐜𝐞𝐬 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧 𝐰𝐢𝐭𝐡 𝐁𝐫𝐢𝐬𝐭𝐨𝐥 𝐌𝐲𝐞𝐫𝐬 𝐒𝐪𝐮𝐢𝐛𝐛 𝐨𝐧 𝐏𝐞𝐩𝐭𝐢𝐝𝐞 𝐌𝐚𝐜𝐫𝐨𝐜𝐲𝐜𝐥𝐞 𝐎𝐩𝐭𝐢𝐦𝐢𝐳𝐚𝐭𝐢𝐨𝐧 Menten AI, Inc. Menten AI, a biotechnology company specializing in generative AI for peptide macrocycle design, announced a research collaboration and licensing agreement with Bristol Myers Squibb Bristol Myers Squibb. Menten AI’s platform uses machine learning, physics-based models, and quantum chemistry to optimize peptide macrocycles, reducing the number of candidate molecules needed for testing and iterations required to achieve drug-like properties. Through this collaboration, Menten AI and Bristol Myers Squibb Bristol Myers Squibb optimized the biochemical properties of certain peptide macrocycles, identifying new amino acid modifications. “This is a key milestone for Menten AI, demonstrating the maturity of our platform and generative AI to accelerate the discovery and optimization of next-generation peptide macrocycles,” noted Hans Melo Hans Melo, co-founder and CEO of Menten AI. #Biotech #AI #Pharma #DrugDiscovery #PeptideResearch #MachineLearning #HealthcareInnovation #Pharmaceuticals #GenerativeAI #ResearchCollaboration #MedicalResearch #Innovation #QuantumChemistry

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics